Jim Miller - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Jim Miller


Jim Miller Pharmtech contributing editor and EAB member

Jim Miller
President, PharmSource Information Services,
Bio/Pharmaceutical Outsourcing Report

PharmTech Contributing editor, Outsourcing Outlook

Jim Miller is the founder and president of PharmSource. A preeminent expert in bio/pharmaceutical outsourcing, Jim established and presides over the pharmaceutical industry’s principal source of market intelligence on the business of contract research, development and manufacturing of bio/pharmaceuticals. PharmSource’s subscription databases, reports and consulting services are used by major pharmaceutical companies, contract manufacturers and contract research organizations to understand key market trends, identify new business opportunities and establish effective business and sourcing strategies. Jim writes regular columns on outsourcing for Pharmaceutical Technology, Pharmaceutical Technology Europe, and BioPharm magazines.

Jim’s other career highlights include a stint as president and chief operating officer of St. Anthony Publishing, a pioneering provider of value-added information services to hospitals and physician practices. He was a consultant in corporate strategy with the Boston Consulting Group, a project economist for the World Bank, and a Peace Corps volunteer in Botswana. He holds an MBA degree from the Stanford University Graduate School of Business.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
30%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
8%
All of the above.
45%
No government involvement in patient treatment or drug development.
8%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics

Click here